↓ Skip to main content

Dove Medical Press

Article Metrics

Agomelatine as monotherapy for major depression: an outpatient, open-label study

Overview of attention for article published in Neuropsychiatric Disease and Treatment, October 2013
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (51st percentile)

Mentioned by

twitter
3 tweeters

Readers on

mendeley
21 Mendeley
Title
Agomelatine as monotherapy for major depression: an outpatient, open-label study
Published in
Neuropsychiatric Disease and Treatment, October 2013
DOI 10.2147/ndt.s49062
Pubmed ID
Authors

Jan Pecenak

Abstract

Agomelatine is a novel antidepressant agonist to MT1 and MT2 subtypes of melatoninergic receptors (MT1 and MT2) and antagonist to 5-HT2C subtype of serotonergic (5-HT2C) receptors, which has shown antidepressant efficacy in short-term and long-term trials as well as in clinical practice. The purpose of this study was to assess the antidepressant efficacy, safety, and the influence of agomelatine on the functioning of patient in common clinical practice.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 21 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 29%
Student > Ph. D. Student 4 19%
Student > Bachelor 2 10%
Student > Doctoral Student 2 10%
Professor 2 10%
Other 4 19%
Unknown 1 5%
Readers by discipline Count As %
Medicine and Dentistry 7 33%
Agricultural and Biological Sciences 5 24%
Nursing and Health Professions 2 10%
Psychology 2 10%
Unspecified 1 5%
Other 0 0%
Unknown 4 19%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 November 2013.
All research outputs
#2,121,822
of 4,508,238 outputs
Outputs from Neuropsychiatric Disease and Treatment
#451
of 908 outputs
Outputs of similar age
#45,768
of 101,876 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#24
of 54 outputs
Altmetric has tracked 4,508,238 research outputs across all sources so far. This one is in the 49th percentile – i.e., 49% of other outputs scored the same or lower than it.
So far Altmetric has tracked 908 research outputs from this source. They receive a mean Attention Score of 3.2. This one is in the 37th percentile – i.e., 37% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 101,876 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.
We're also able to compare this research output to 54 others from the same source and published within six weeks on either side of this one. This one is in the 24th percentile – i.e., 24% of its contemporaries scored the same or lower than it.